Startup Wugen raises $115M for ‘off-the-shelf’ CAR-T
Written by
BioPharma Dive
Published
0
comments
0
min
The St. Louis-based biotech hopes to submit an application for its leukemia and lymphoma therapy in 2027, if all goes well in an ongoing trial.